Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems, Inc. (RPID) Stock Competitors & Peer Comparison
See (RPID) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPID | $2.53 | +2.02% | 115.3M | -2.52 | -$1.00 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $86.30 | -1.00% | 150.2B | 24.16 | $3.57 | +2.82% |
| SYK | $292.33 | -0.99% | 111.9B | 34.80 | $8.40 | +1.18% |
| MDT | $77.60 | -0.24% | 99.6B | 21.68 | $3.58 | +3.66% |
| BSX | $56.00 | +0.04% | 83.3B | 23.44 | $2.39 | N/A |
| BRKRP | $330.36 | +9.98% | 50.1B | N/A | N/A | +0.48% |
| EW | $83.20 | +0.35% | 48B | 44.97 | $1.85 | N/A |
| PHG | $27.23 | +2.95% | 25.9B | 24.97 | $1.09 | +3.54% |
| DXCM | $60.36 | +1.48% | 23.3B | 25.89 | $2.33 | N/A |
Stock Comparison
RPID vs BSX-PA Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RPID is priced at $2.53, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RPID's ROE is -0.95%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BSX-PA's competition here
RPID vs ABT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ABT has a market cap of 150.2B. Regarding current trading prices, RPID is priced at $2.53, while ABT trades at $86.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ABT's P/E ratio is 24.16. In terms of profitability, RPID's ROE is -0.95%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RPID is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ABT's competition here
RPID vs SYK Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SYK has a market cap of 111.9B. Regarding current trading prices, RPID is priced at $2.53, while SYK trades at $292.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SYK's P/E ratio is 34.80. In terms of profitability, RPID's ROE is -0.95%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SYK's competition here
RPID vs MDT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, MDT has a market cap of 99.6B. Regarding current trading prices, RPID is priced at $2.53, while MDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas MDT's P/E ratio is 21.68. In terms of profitability, RPID's ROE is -0.95%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check MDT's competition here
RPID vs BSX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BSX has a market cap of 83.3B. Regarding current trading prices, RPID is priced at $2.53, while BSX trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BSX's P/E ratio is 23.44. In terms of profitability, RPID's ROE is -0.95%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BSX's competition here
RPID vs BRKRP Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BRKRP has a market cap of 50.1B. Regarding current trading prices, RPID is priced at $2.53, while BRKRP trades at $330.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BRKRP's P/E ratio is N/A. In terms of profitability, RPID's ROE is -0.95%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, RPID is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BRKRP's competition here
RPID vs EW Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, EW has a market cap of 48B. Regarding current trading prices, RPID is priced at $2.53, while EW trades at $83.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas EW's P/E ratio is 44.97. In terms of profitability, RPID's ROE is -0.95%, compared to EW's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check EW's competition here
RPID vs PHG Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PHG has a market cap of 25.9B. Regarding current trading prices, RPID is priced at $2.53, while PHG trades at $27.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PHG's P/E ratio is 24.97. In terms of profitability, RPID's ROE is -0.95%, compared to PHG's ROE of +0.08%. Regarding short-term risk, RPID is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PHG's competition here
RPID vs DXCM Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, DXCM has a market cap of 23.3B. Regarding current trading prices, RPID is priced at $2.53, while DXCM trades at $60.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas DXCM's P/E ratio is 25.89. In terms of profitability, RPID's ROE is -0.95%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RPID and DXCM have similar daily volatility (3.97).Check DXCM's competition here
RPID vs STE Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, STE has a market cap of 21.1B. Regarding current trading prices, RPID is priced at $2.53, while STE trades at $214.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas STE's P/E ratio is 30.25. In terms of profitability, RPID's ROE is -0.95%, compared to STE's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check STE's competition here
RPID vs ABMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RPID is priced at $2.53, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RPID's ROE is -0.95%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ABMD's competition here
RPID vs ZBH Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ZBH has a market cap of 16B. Regarding current trading prices, RPID is priced at $2.53, while ZBH trades at $82.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ZBH's P/E ratio is 21.51. In terms of profitability, RPID's ROE is -0.95%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RPID is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ZBH's competition here
RPID vs SNN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, RPID is priced at $2.53, while SNN trades at $30.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SNN's P/E ratio is 21.15. In terms of profitability, RPID's ROE is -0.95%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RPID is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SNN's competition here
RPID vs PEN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, RPID is priced at $2.53, while PEN trades at $324.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PEN's P/E ratio is 71.58. In terms of profitability, RPID's ROE is -0.95%, compared to PEN's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PEN's competition here
RPID vs SWAV Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RPID is priced at $2.53, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RPID's ROE is -0.95%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RPID is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SWAV's competition here
RPID vs ALGN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, RPID is priced at $2.53, while ALGN trades at $173.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ALGN's P/E ratio is 29.17. In terms of profitability, RPID's ROE is -0.95%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ALGN's competition here
RPID vs GMED Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, GMED has a market cap of 12.1B. Regarding current trading prices, RPID is priced at $2.53, while GMED trades at $89.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas GMED's P/E ratio is 22.75. In terms of profitability, RPID's ROE is -0.95%, compared to GMED's ROE of +0.12%. Regarding short-term risk, RPID is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check GMED's competition here
RPID vs PODD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, RPID is priced at $2.53, while PODD trades at $151.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PODD's P/E ratio is 43.45. In terms of profitability, RPID's ROE is -0.95%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RPID is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PODD's competition here
RPID vs GKOS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, GKOS has a market cap of 8B. Regarding current trading prices, RPID is priced at $2.53, while GKOS trades at $135.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas GKOS's P/E ratio is -41.03. In terms of profitability, RPID's ROE is -0.95%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RPID is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check GKOS's competition here
RPID vs BIO Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BIO has a market cap of 7B. Regarding current trading prices, RPID is priced at $2.53, while BIO trades at $259.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BIO's P/E ratio is 43.18. In terms of profitability, RPID's ROE is -0.95%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RPID is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BIO's competition here
RPID vs BIO-B Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BIO-B has a market cap of 7B. Regarding current trading prices, RPID is priced at $2.53, while BIO-B trades at $261.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BIO-B's P/E ratio is 42.93. In terms of profitability, RPID's ROE is -0.95%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RPID is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BIO-B's competition here
RPID vs BRKR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, RPID is priced at $2.53, while BRKR trades at $42.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BRKR's P/E ratio is -282.07. In terms of profitability, RPID's ROE is -0.95%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RPID is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BRKR's competition here
RPID vs NARI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RPID is priced at $2.53, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas NARI's P/E ratio is -59.24. In terms of profitability, RPID's ROE is -0.95%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RPID is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NARI's competition here
RPID vs IRTC Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, RPID is priced at $2.53, while IRTC trades at $117.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas IRTC's P/E ratio is -138.68. In terms of profitability, RPID's ROE is -0.95%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RPID is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check IRTC's competition here
RPID vs AXNX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RPID is priced at $2.53, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RPID's ROE is -0.95%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RPID is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AXNX's competition here
RPID vs LIVN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, LIVN has a market cap of 3.6B. Regarding current trading prices, RPID is priced at $2.53, while LIVN trades at $66.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas LIVN's P/E ratio is -14.87. In terms of profitability, RPID's ROE is -0.95%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RPID is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check LIVN's competition here
RPID vs ITGR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, RPID is priced at $2.53, while ITGR trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ITGR's P/E ratio is 21.38. In terms of profitability, RPID's ROE is -0.95%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RPID is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ITGR's competition here
RPID vs TMDX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, RPID is priced at $2.53, while TMDX trades at $72.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas TMDX's P/E ratio is 14.97. In terms of profitability, RPID's ROE is -0.95%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RPID is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TMDX's competition here
RPID vs AXGN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, RPID is priced at $2.53, while AXGN trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AXGN's P/E ratio is -68.97. In terms of profitability, RPID's ROE is -0.95%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RPID is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AXGN's competition here
RPID vs ESTA Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, RPID is priced at $2.53, while ESTA trades at $74.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ESTA's P/E ratio is -43.37. In terms of profitability, RPID's ROE is -0.95%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RPID is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ESTA's competition here
RPID vs NUVA Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RPID is priced at $2.53, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RPID's ROE is -0.95%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RPID is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NUVA's competition here
RPID vs UFPT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $2.53, while UFPT trades at $218.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas UFPT's P/E ratio is 24.98. In terms of profitability, RPID's ROE is -0.95%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RPID is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check UFPT's competition here
RPID vs AORT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $2.53, while AORT trades at $34.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AORT's P/E ratio is 165.31. In terms of profitability, RPID's ROE is -0.95%, compared to AORT's ROE of +0.02%. Regarding short-term risk, RPID is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check AORT's competition here
RPID vs AHCO Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, RPID is priced at $2.53, while AHCO trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AHCO's P/E ratio is -19.33. In terms of profitability, RPID's ROE is -0.95%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RPID is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check AHCO's competition here
RPID vs PRCT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $2.53, while PRCT trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PRCT's P/E ratio is -13.55. In terms of profitability, RPID's ROE is -0.95%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RPID is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PRCT's competition here
RPID vs INSP Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.53, while INSP trades at $45.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas INSP's P/E ratio is 10.39. In terms of profitability, RPID's ROE is -0.95%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RPID is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check INSP's competition here
RPID vs HSKA Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $2.53, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RPID's ROE is -0.95%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RPID is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check HSKA's competition here
RPID vs TNDM Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, RPID is priced at $2.53, while TNDM trades at $18.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas TNDM's P/E ratio is -5.93. In terms of profitability, RPID's ROE is -0.95%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, RPID is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TNDM's competition here
RPID vs BFLY Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, RPID is priced at $2.53, while BFLY trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BFLY's P/E ratio is -15.15. In terms of profitability, RPID's ROE is -0.95%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RPID is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BFLY's competition here
RPID vs AVNS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RPID is priced at $2.53, while AVNS trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AVNS's P/E ratio is -15.75. In terms of profitability, RPID's ROE is -0.95%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RPID is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AVNS's competition here
RPID vs CNMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while CNMD trades at $37.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CNMD's P/E ratio is 21.08. In terms of profitability, RPID's ROE is -0.95%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RPID is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CNMD's competition here
RPID vs SILK Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SILK's P/E ratio is -18.96. In terms of profitability, RPID's ROE is -0.95%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RPID is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SILK's competition here
RPID vs IRMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while IRMD trades at $86.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas IRMD's P/E ratio is 47.14. In terms of profitability, RPID's ROE is -0.95%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RPID is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check IRMD's competition here
RPID vs FNA Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas FNA's P/E ratio is -19.83. In terms of profitability, RPID's ROE is -0.95%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RPID is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check FNA's competition here
RPID vs IART Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while IART trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas IART's P/E ratio is -2.17. In terms of profitability, RPID's ROE is -0.95%, compared to IART's ROE of -0.48%. Regarding short-term risk, RPID is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check IART's competition here
RPID vs ATEC Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $2.53, while ATEC trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ATEC's P/E ratio is -7.27. In terms of profitability, RPID's ROE is -0.95%, compared to ATEC's ROE of -1.42%. Regarding short-term risk, RPID is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ATEC's competition here
RPID vs LMRI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, LMRI has a market cap of 989M. Regarding current trading prices, RPID is priced at $2.53, while LMRI trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas LMRI's P/E ratio is -15.59. In terms of profitability, RPID's ROE is -0.95%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, RPID is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check LMRI's competition here
RPID vs INMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, INMD has a market cap of 862.3M. Regarding current trading prices, RPID is priced at $2.53, while INMD trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas INMD's P/E ratio is 9.52. In terms of profitability, RPID's ROE is -0.95%, compared to INMD's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check INMD's competition here
RPID vs CSII Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RPID is priced at $2.53, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CSII's P/E ratio is -20.83. In terms of profitability, RPID's ROE is -0.95%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RPID is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CSII's competition here
RPID vs SSII Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SSII has a market cap of 819.5M. Regarding current trading prices, RPID is priced at $2.53, while SSII trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SSII's P/E ratio is -68.25. In terms of profitability, RPID's ROE is -0.95%, compared to SSII's ROE of -0.30%. Regarding short-term risk, RPID is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SSII's competition here
RPID vs CBLL Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CBLL has a market cap of 762.4M. Regarding current trading prices, RPID is priced at $2.53, while CBLL trades at $20.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CBLL's P/E ratio is -13.79. In terms of profitability, RPID's ROE is -0.95%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, RPID is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CBLL's competition here
RPID vs BVS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BVS has a market cap of 737.9M. Regarding current trading prices, RPID is priced at $2.53, while BVS trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BVS's P/E ratio is 33.06. In terms of profitability, RPID's ROE is -0.95%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RPID is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BVS's competition here
RPID vs CRY Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RPID is priced at $2.53, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CRY's P/E ratio is 425.71. In terms of profitability, RPID's ROE is -0.95%, compared to CRY's ROE of +0.02%. Regarding short-term risk, RPID is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CRY's competition here
RPID vs BWAY Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BWAY has a market cap of 643.3M. Regarding current trading prices, RPID is priced at $2.53, while BWAY trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BWAY's P/E ratio is 91.11. In terms of profitability, RPID's ROE is -0.95%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BWAY's competition here
RPID vs CTKB Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CTKB has a market cap of 634.4M. Regarding current trading prices, RPID is priced at $2.53, while CTKB trades at $4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CTKB's P/E ratio is -9.49. In terms of profitability, RPID's ROE is -0.95%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, RPID is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CTKB's competition here
RPID vs NPCE Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, NPCE has a market cap of 615M. Regarding current trading prices, RPID is priced at $2.53, while NPCE trades at $18.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas NPCE's P/E ratio is -27.45. In terms of profitability, RPID's ROE is -0.95%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, RPID is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check NPCE's competition here
RPID vs SRDX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RPID is priced at $2.53, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RPID's ROE is -0.95%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, RPID is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SRDX's competition here
RPID vs APEN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RPID is priced at $2.53, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas APEN's P/E ratio is -9.43. In terms of profitability, RPID's ROE is -0.95%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RPID is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check APEN's competition here
RPID vs SIBN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SIBN has a market cap of 574.7M. Regarding current trading prices, RPID is priced at $2.53, while SIBN trades at $12.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SIBN's P/E ratio is -29.52. In terms of profitability, RPID's ROE is -0.95%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, RPID is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SIBN's competition here
RPID vs TCMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, TCMD has a market cap of 571.1M. Regarding current trading prices, RPID is priced at $2.53, while TCMD trades at $25.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas TCMD's P/E ratio is 29.10. In terms of profitability, RPID's ROE is -0.95%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RPID is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TCMD's competition here
RPID vs ZIMV Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RPID is priced at $2.53, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RPID's ROE is -0.95%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RPID is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ZIMV's competition here
RPID vs PACB Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PACB has a market cap of 519.4M. Regarding current trading prices, RPID is priced at $2.53, while PACB trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PACB's P/E ratio is -0.95. In terms of profitability, RPID's ROE is -0.95%, compared to PACB's ROE of -11.23%. Regarding short-term risk, RPID is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PACB's competition here
RPID vs CERS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CERS has a market cap of 519M. Regarding current trading prices, RPID is priced at $2.53, while CERS trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CERS's P/E ratio is -51.80. In terms of profitability, RPID's ROE is -0.95%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RPID is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CERS's competition here
RPID vs VREX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, VREX has a market cap of 509.6M. Regarding current trading prices, RPID is priced at $2.53, while VREX trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas VREX's P/E ratio is -7.41. In terms of profitability, RPID's ROE is -0.95%, compared to VREX's ROE of -0.14%. Regarding short-term risk, RPID is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check VREX's competition here
RPID vs OFIX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, OFIX has a market cap of 489.8M. Regarding current trading prices, RPID is priced at $2.53, while OFIX trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas OFIX's P/E ratio is -5.24. In terms of profitability, RPID's ROE is -0.95%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RPID is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check OFIX's competition here
RPID vs KIDS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, KIDS has a market cap of 440.5M. Regarding current trading prices, RPID is priced at $2.53, while KIDS trades at $17.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas KIDS's P/E ratio is -10.21. In terms of profitability, RPID's ROE is -0.95%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RPID is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check KIDS's competition here
RPID vs DCTH Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, DCTH has a market cap of 390.7M. Regarding current trading prices, RPID is priced at $2.53, while DCTH trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas DCTH's P/E ratio is 160.64. In terms of profitability, RPID's ROE is -0.95%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, RPID is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check DCTH's competition here
RPID vs LAB Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, LAB has a market cap of 380.6M. Regarding current trading prices, RPID is priced at $2.53, while LAB trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas LAB's P/E ratio is -6.50. In terms of profitability, RPID's ROE is -0.95%, compared to LAB's ROE of +0.17%. Regarding short-term risk, RPID is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check LAB's competition here
RPID vs PMI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PMI has a market cap of 353.5M. Regarding current trading prices, RPID is priced at $2.53, while PMI trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PMI's P/E ratio is -0.30. In terms of profitability, RPID's ROE is -0.95%, compared to PMI's ROE of +2.17%. Regarding short-term risk, RPID is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PMI's competition here
RPID vs CLPT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CLPT has a market cap of 343.9M. Regarding current trading prices, RPID is priced at $2.53, while CLPT trades at $11.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CLPT's P/E ratio is -13.03. In terms of profitability, RPID's ROE is -0.95%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, RPID is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CLPT's competition here
RPID vs VMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, VMD has a market cap of 327.7M. Regarding current trading prices, RPID is priced at $2.53, while VMD trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas VMD's P/E ratio is 23.01. In terms of profitability, RPID's ROE is -0.95%, compared to VMD's ROE of +0.11%. Regarding short-term risk, RPID is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check VMD's competition here
RPID vs SMLR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RPID is priced at $2.53, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RPID's ROE is -0.95%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RPID is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SMLR's competition here
RPID vs MASS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, MASS has a market cap of 301.3M. Regarding current trading prices, RPID is priced at $2.53, while MASS trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas MASS's P/E ratio is -8.67. In terms of profitability, RPID's ROE is -0.95%, compared to MASS's ROE of -0.26%. Regarding short-term risk, RPID is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check MASS's competition here
RPID vs CATX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CATX has a market cap of 281M. Regarding current trading prices, RPID is priced at $2.53, while CATX trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CATX's P/E ratio is -2.71. In terms of profitability, RPID's ROE is -0.95%, compared to CATX's ROE of -0.41%. Regarding short-term risk, RPID is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CATX's competition here
RPID vs RXST Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, RXST has a market cap of 279.8M. Regarding current trading prices, RPID is priced at $2.53, while RXST trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas RXST's P/E ratio is -7.14. In terms of profitability, RPID's ROE is -0.95%, compared to RXST's ROE of -0.14%. Regarding short-term risk, RPID is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check RXST's competition here
RPID vs MGRM Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RPID is priced at $2.53, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas MGRM's P/E ratio is -11.11. In terms of profitability, RPID's ROE is -0.95%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, RPID is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check MGRM's competition here
RPID vs AVR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, AVR has a market cap of 234.7M. Regarding current trading prices, RPID is priced at $2.53, while AVR trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas AVR's P/E ratio is -2.50. In terms of profitability, RPID's ROE is -0.95%, compared to AVR's ROE of -5.28%. Regarding short-term risk, RPID is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check AVR's competition here
RPID vs SGHT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SGHT has a market cap of 233.3M. Regarding current trading prices, RPID is priced at $2.53, while SGHT trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SGHT's P/E ratio is -5.84. In terms of profitability, RPID's ROE is -0.95%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, RPID is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SGHT's competition here
RPID vs NVRO Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RPID is priced at $2.53, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RPID's ROE is -0.95%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RPID is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NVRO's competition here
RPID vs SENS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SENS has a market cap of 224M. Regarding current trading prices, RPID is priced at $2.53, while SENS trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SENS's P/E ratio is -3.23. In terms of profitability, RPID's ROE is -0.95%, compared to SENS's ROE of -1.04%. Regarding short-term risk, RPID is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SENS's competition here
RPID vs PROF Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, PROF has a market cap of 218.2M. Regarding current trading prices, RPID is priced at $2.53, while PROF trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas PROF's P/E ratio is -5.11. In terms of profitability, RPID's ROE is -0.95%, compared to PROF's ROE of -0.80%. Regarding short-term risk, RPID is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PROF's competition here
RPID vs ELMD Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ELMD has a market cap of 214.9M. Regarding current trading prices, RPID is priced at $2.53, while ELMD trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ELMD's P/E ratio is 25.21. In terms of profitability, RPID's ROE is -0.95%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, RPID is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ELMD's competition here
RPID vs EYES Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RPID is priced at $2.53, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas EYES's P/E ratio is N/A. In terms of profitability, RPID's ROE is -0.95%, compared to EYES's ROE of -3.17%. Regarding short-term risk, RPID is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check EYES's competition here
RPID vs ANIK Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, ANIK has a market cap of 201.2M. Regarding current trading prices, RPID is priced at $2.53, while ANIK trades at $15.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas ANIK's P/E ratio is -19.14. In terms of profitability, RPID's ROE is -0.95%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RPID is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ANIK's competition here
RPID vs INGN Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, INGN has a market cap of 194M. Regarding current trading prices, RPID is priced at $2.53, while INGN trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas INGN's P/E ratio is -8.26. In terms of profitability, RPID's ROE is -0.95%, compared to INGN's ROE of -0.12%. Regarding short-term risk, RPID is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check INGN's competition here
RPID vs QTI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, QTI has a market cap of 192.4M. Regarding current trading prices, RPID is priced at $2.53, while QTI trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas QTI's P/E ratio is -3.53. In terms of profitability, RPID's ROE is -0.95%, compared to QTI's ROE of +3.64%. Regarding short-term risk, RPID is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check QTI's competition here
RPID vs BSGM Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RPID is priced at $2.53, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RPID's ROE is -0.95%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RPID is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BSGM's competition here
RPID vs CVRX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, CVRX has a market cap of 186.2M. Regarding current trading prices, RPID is priced at $2.53, while CVRX trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas CVRX's P/E ratio is -3.47. In terms of profitability, RPID's ROE is -0.95%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, RPID is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CVRX's competition here
RPID vs MDGS Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RPID is priced at $2.53, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RPID's ROE is -0.95%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RPID is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check MDGS's competition here
RPID vs TLSI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, TLSI has a market cap of 172.9M. Regarding current trading prices, RPID is priced at $2.53, while TLSI trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas TLSI's P/E ratio is -2.48. In terms of profitability, RPID's ROE is -0.95%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, RPID is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check TLSI's competition here
RPID vs QIPT Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RPID is priced at $2.53, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RPID's ROE is -0.95%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RPID is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check QIPT's competition here
RPID vs QTRX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, QTRX has a market cap of 154.9M. Regarding current trading prices, RPID is priced at $2.53, while QTRX trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas QTRX's P/E ratio is -1.31. In terms of profitability, RPID's ROE is -0.95%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RPID is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check QTRX's competition here
RPID vs HYPR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, HYPR has a market cap of 143M. Regarding current trading prices, RPID is priced at $2.53, while HYPR trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas HYPR's P/E ratio is -4.07. In terms of profitability, RPID's ROE is -0.95%, compared to HYPR's ROE of -0.97%. Regarding short-term risk, RPID is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check HYPR's competition here
RPID vs SNWV Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, SNWV has a market cap of 136.7M. Regarding current trading prices, RPID is priced at $2.53, while SNWV trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas SNWV's P/E ratio is 38.80. In terms of profitability, RPID's ROE is -0.95%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, RPID is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SNWV's competition here
RPID vs EDAP Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, EDAP has a market cap of 135.7M. Regarding current trading prices, RPID is priced at $2.53, while EDAP trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas EDAP's P/E ratio is -4.64. In terms of profitability, RPID's ROE is -0.95%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, RPID is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check EDAP's competition here
RPID vs TMCI Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, TMCI has a market cap of 124.4M. Regarding current trading prices, RPID is priced at $2.53, while TMCI trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas TMCI's P/E ratio is -2.09. In terms of profitability, RPID's ROE is -0.95%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, RPID is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TMCI's competition here
RPID vs NNOX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, NNOX has a market cap of 123.9M. Regarding current trading prices, RPID is priced at $2.53, while NNOX trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas NNOX's P/E ratio is -1.53. In terms of profitability, RPID's ROE is -0.95%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, RPID is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check NNOX's competition here
RPID vs APYX Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, APYX has a market cap of 121.7M. Regarding current trading prices, RPID is priced at $2.53, while APYX trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas APYX's P/E ratio is -10.78. In terms of profitability, RPID's ROE is -0.95%, compared to APYX's ROE of -1.18%. Regarding short-term risk, RPID is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check APYX's competition here
RPID vs FONR Comparison May 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 115.3M. In comparison, FONR has a market cap of 116.6M. Regarding current trading prices, RPID is priced at $2.53, while FONR trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -2.52, whereas FONR's P/E ratio is 16.42. In terms of profitability, RPID's ROE is -0.95%, compared to FONR's ROE of +0.04%. Regarding short-term risk, RPID is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check FONR's competition here